{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T17:42:15Z","timestamp":1782582135710,"version":"3.54.5"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"vor","delay-in-days":241,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.ctarc.2023.100757","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T07:25:11Z","timestamp":1693466711000},"page":"100757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Sotorasib after immune checkpoint inhibitor administration induces hepatotoxicity. True, false or just another adverse effect of NSCLC treatment"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5119-2207","authenticated-orcid":false,"given":"Paul","family":"Zarogoulidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris","family":"Matthaios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagoula","family":"Oikonomou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Nikolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Charalampidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysanthi","family":"Sardeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2023.100757_bib0001","first-page":"3419","article-title":"Tumor molecular profiling of NSCLC patients using next generation sequencing","volume":"38","author":"Tsoulos","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ctarc.2023.100757_bib0002","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3390\/curroncol29020057","article-title":"ROS-1 fusions in non-small-cell lung cancer: evidence to date","volume":"29","author":"Gendarme","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ctarc.2023.100757_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100280","article-title":"Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies","volume":"6","author":"Di Noia","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctarc.2023.100757_bib0004","doi-asserted-by":"crossref","first-page":"6890","DOI":"10.18632\/aging.202547","article-title":"MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET\/Akt\/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts","volume":"13","author":"Zhu","year":"2021","journal-title":"Aging"},{"key":"10.1016\/j.ctarc.2023.100757_bib0005","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/mco2.105","article-title":"Therapeutic advances in non-small cell lung cancer: focus on clinical development of targeted therapy and immunotherapy","volume":"2","author":"Cheng","year":"2021","journal-title":"MedComm"},{"key":"10.1016\/j.ctarc.2023.100757_bib0006","first-page":"1","article-title":"Immunotherapy in non-small cell lung cancer: update and new insights","volume":"7","author":"Mielgo-Rubio","year":"2021","journal-title":"J. Clin. Transl. Res."},{"key":"10.1016\/j.ctarc.2023.100757_bib0007","doi-asserted-by":"crossref","first-page":"S395","DOI":"10.21037\/jtd.2017.03.158","article-title":"Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)-from morphology to molecular testing","volume":"9","author":"Righi","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.ctarc.2023.100757_bib0008","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2023.100757_bib0009","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.7150\/jca.84894","article-title":"Endobronchial Radiofrequency Ablation for pulmonary nodules with Radial\u2013Ebus and navigation: pros and cons","volume":"14","author":"Zarogoulidis","year":"2023","journal-title":"J. Cancer"},{"key":"10.1016\/j.ctarc.2023.100757_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19063569","article-title":"Radial-EBUS: CryoBiopsy versus conventional biopsy: time-sample and C-arm","volume":"19","author":"Zarogoulidis","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.ctarc.2023.100757_bib0011","doi-asserted-by":"crossref","first-page":"6454","DOI":"10.7150\/jca.48691","article-title":"Lung cancer biopsies: comparison between simple 22G, 22G upgraded and 21G needle for EBUS-TBNA","volume":"11","author":"Zarogoulidis","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.ctarc.2023.100757_bib0012","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ctarc.2023.100757_bib0013","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdt205","article-title":"Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)","volume":"24","author":"Dearden","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2023.100757_bib0014","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12943-018-0789-x","article-title":"KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target","volume":"17","author":"Roman","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ctarc.2023.100757_bib0015","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ctarc.2023.100757_bib0016","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2017.3438","article-title":"Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: the SELECT-1 randomized clinical trial","volume":"317","author":"Janne","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ctarc.2023.100757_bib0017","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jtho.2016.11.2218","article-title":"A phase 1\/1b study evaluating trametinib plus docetaxel or pemetrexed in patients with advanced non-small cell lung cancer","volume":"12","author":"Gandara","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2023.100757_bib0018","article-title":"Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: a brief report","volume":"36","author":"Desai","year":"2023","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.ctarc.2023.100757_bib0019","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jtho.2022.01.012","article-title":"Osimertinib plus durvalumab in patients with EGFR-mutated, advanced NSCLC: a phase 1b, open-label, multicenter trial","volume":"17","author":"Ahn","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2023.100757_bib0020","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jtho.2018.09.001","article-title":"Increased hepatotoxicity associated with sequential immune checkpoint inhibitor and crizotinib therapy in patients with non-small cell lung cancer","volume":"14","author":"Lin","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2023.100757_bib0021","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumor immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294223000795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294223000795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T19:22:09Z","timestamp":1722972129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294223000795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":21,"alternative-id":["S2468294223000795"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2023.100757","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sotorasib after immune checkpoint inhibitor administration induces hepatotoxicity. True, false or just another adverse effect of NSCLC treatment","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2023.100757","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100757"}}